Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HW231019
- Development stage
- Preclinical
- Lead developer
- Yichang Humanwell Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
HW231019 is an investigational small molecule drug developed by Wuhan Humanwell Hi-Tech Industry for the treatment of acute and chronic pain. It is classified as a Class 1 chemical drug in China, signifying that it is a new chemical entity (NCE). The drug is formulated as an oral tablet. Currently in the early stages of development, HW231019 is part of the company's research and development pipeline focused on anesthesiology and analgesia. While its specific molecular target and mechanism of action have not been publicly disclosed, it is being positioned as a potential therapeutic option for various pain conditions.
- Other names
- HW231019片及原料药
Beyond the preview
Go deeper on HW231019.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HW231019.